OnKure increased R&D spending in 1Q with drug trials underway
OnKure Therapeutics Inc., a Boulder precision oncology company that went public last year via a merger with California-based Reneo Pharmaceuticals Inc., saw its net losses grow in the first quarter of 2025 as research and development spending increased with several drug trials underway.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Downtown Loveland’s Foundry Plaza will host the fifth annual One Sweet Summer: Bluegrass & Brews…
-
A federal judge in Massachusetts issued a nationwide block Wednesday on an effort by President…
-
Fee increases for development review and building permits in Loveland will go into effect June…
-
A federal judge in Rhode Island will temporarily block President Donald Trump’s administration from cutting…
